Texas House of Representatives · 89th Legislature, Regular Session
Members who authored, joint-authored, or co-sponsored this bill.
SourceLegiScan (CC BY 4.0)89R
AI summary unavailable. We’re still building out our data, so newer and more active legislation has better coverage.
Each version links to the authoritative document on capitol.texas.gov.
89R8229 JTZ-F By: Oliverson H.B. No. 3086 A BILL TO BE ENTITLED AN ACT relating to requirements for pharmaceutical drug manufacturers to report prescription drug costs. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. Section 441.0051, Health and Safety Code, is amended to read as follows: Sec. 441.0051. ANNUAL REPORT. (a) Not later than the 15th
day of each calendar year, a pharmaceutical drug manufacturer shall submit a report to the department stating the current wholesale acquisition cost information for the United States Food and Drug Administration-approved prescription drugs sold in or into this state by that manufacturer. (b) For a prescription drug with a wholesale acquisition cost increase of 40 percent or more over the drug's wholesale acquisition cost in the preceding three calendar years or 15 percent or more in the preceding calendar year, a pharmaceutical drug manufacturer shall include in the annual report required under Subsection (a): (1) information on whether the prescription drug is a brand name drug or generic version of a brand name drug; (2) a statement on each factor that caused the increase in the wholesale acquisition cost and an explanation of the impact of each factor on the cost; (3) aggregate, research, and development costs as filed with United States Securities and Exchange Commission on Form 10-K for the most recent calendar year for which final audit data is available; (4) the name of each of the manufacturer's prescription drugs the United States Food and Drug Administration approved in the previous three calendar years; and (5) the name of each of the manufacturer's prescription drugs that lost patent exclusivity in the United States in the previous three calendar years. (c) The information a pharmaceutical drug manufacturer submits to the department under Subsections (a) and (b) must be consistent with the information the manufacturer includes in the manufacturer's annual consolidated report filed with the United States Securities and Exchange Commission on Form 10-K or any other public disclosure. SECTION 2. Section 441.0054, Health and Safety Code, is amended to read as follows: Sec. 441.0054. PUBLICATION OF COST INCREASE INFORMATION. Not later than the 60th day after receipt of the report submitted under Section 441.0051 [ or 441.0053(a) ], the department shall publish the required cost increase information [ required by Section 441.0053 ] on the department's prescription drug price information Internet website. SECTION 3. Section 441.0102(a), Health and Safety Code, is amended to read as follows: (a) The department shall [ may ] assess an administrative penalty against a person who violates this chapter or a rule adopted under this chapter. SECTION 4. Section 441.0053, Health and Safety Code, is repealed. SECTION 5. As soon as practicable after the effective date of this Act, the executive commissioner of the Health and Human Services Commission shall adopt rules necessary to implement the changes in law made by this Act. SECTION 6. This Act takes effect September 1, 2025.
SourceTexas Legislative Council (capitol.texas.gov)official bill text (capitol.texas.gov)
Statewide figures for the subjects tagged on this bill, to explore on the Data map. They describe Texas — not this bill or its effects.
SourceU.S. Census Bureau (ACS) & CDC PLACESstatewide Data layer
Each subject links to other 89R bills tagged the same way.
SourceTexas Legislative Council (capitol.texas.gov)89R
No recorded roll-call votes on this bill.
SourceLegiScan (CC BY 4.0)89R
No fiscal notes or analyses recorded for this bill.
SourceLegiScan (CC BY 4.0)official fiscal notes & analyses (TLC)
Perch never collects comments itself — it points you to the Legislature's own hearing schedule and official public-comment channels (ADR-0007).
SourceLegiScan (CC BY 4.0)subject tags